Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Researchers suggest healthcare providers take note of the connection between distress caused by lymphedema and poor mental and physical health and use this information to help women with breast cancer.
Researchers suggest more studies be done on carboplatin to find out if it could have long-term benefits and to see what types of people with triple-negative breast cancer it helps most.
Final results of the phase III TH3RESA trial confirm that the medicine T-DM1 extends progression-free survival, PFS, in people who have HER2-positive metastatic breast cancer that no longer responds well to first-line treatments, such as trastuzumab. PFS is the time from the start of treatment until the disease grows or spreads.
Early results of this study were presented at the European Cancer Congress, in Amsterdam, in the fall of 2013.
An article published in JAMA Surgery suggests that even while some state laws are mandating changes in the way doctors discuss the safety of breast implants and the pros and cons of having immediate or delayed reconstruction, gaps in education still remain.
Final results from the CLEOPATRA trial were presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid at the end of September. The results show the combination of trastuzumab and pertuzumab, along with chemotherapy, lengthened the lives of women with HER2-positive metastatic breast cancer by a median 15.7 months. The increase is being called unprecedented.
According to research, women who have breast implant reconstruction, followed by radiation therapy, are not as happy with the results and report lower levels of well-being than women who have the same reconstruction without radiation therapy.
A recent study of California women with early-stage breast cancer showed that bilateral mastectomy has the same impact on survival as breast-conserving surgery, or lumpectomy, followed by radiation therapy.
After evaluating long-term results from recent studies, the American Society of Clinical Oncology, ASCO, issued a guideline update for tamoxifen therapy for hormone receptor-positive breast cancer.
The update advises doctors to offer up to 10 years of tamoxifen treatment, instead of the previous standard 5-year duration
LBBC highlights results of a phase III clinical trial studying a medicine used to protect premenopausal women’s ovaries during chemotherapy. Findings were announced during the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.
Researchers with the phase II GeparSixto trial found that women with triple-negative breast cancer were significantly more likely to achieve pathological complete response, or pCR, when carboplatin was added to their course of other anti-cancer medicines. For this study, pCR was defined as the absence of cancer after treatment given before surgery.